Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04112498 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04112498 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants.
The verdict
NCT04112498, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will characterize the movement of drugs within the body, evaluate safety and determine to which extent the body can process relatlimab in combination with nivolumab in subjects with certain advanced tumors
Interventions
- DRUG nivolumab
- DRUG rHuPH20
- DRUG relatlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04112498
The ClinicalTrials.gov registry entry for NCT04112498 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nivolumab is the first listed.
NCT04112498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04112498 about?
NCT04112498 is a clinical study titled "A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab". This study will characterize the movement of drugs within the body, evaluate safety and determine to which extent the body can process relatlimab in combination with nivolumab in subjects with certain advanced tumors
What is the current status of trial NCT04112498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-10-01. Estimated completion is 2023-02-27.
What interventions are being tested in trial NCT04112498?
The interventions under investigation include: nivolumab (DRUG), rHuPH20 (DRUG), relatlimab (DRUG).
Who is sponsoring clinical trial NCT04112498?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.